Elixiron Immunotherapeutics (Hong Kong) Ltd.

Quick facts

Phase 2 pipeline

• EI-001 · Oncology
  EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis.
• EI-1071 tablet, oral

Phase 1 pipeline

• EI-1071

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Elixiron Immunotherapeutics (Hong Kong) Ltd. portfolio CI brief
• Elixiron Immunotherapeutics (Hong Kong) Ltd. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies